INDICATION

EVENITY® is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Read More

The anabolic effect of EVENITY® wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY® use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered. Close

EVENITY® resources for patient care EVENITY® resources for patient care

Locate alternative treatment sites where EVENITY® can be administered to your patients.

evenity-finder-webpage
VisitEvenityFinder.com
Bone_Matters_EVENITY_Office_FlashcardccbBone_Matters_EVENITY_Office_Flashcardccb

DOWNLOAD PATIENT DIALOGUE TOOL
english_download

Use and share the EVENITY® Build New Bone dialogue tool during a patient virtual visit to help your patients better understand osteoporosis and EVENITY®.

USA_785_80286_242000971_MACv2ccnUSA_785_80286_242000971_MACv2ccn

DOWNLOAD PATIENT BROCHURE
english_download spanish_download

Share the EVENITY® Patient Brochure with your patients.

Download-Abbreviated-Patient-Brochure-SpanishDownload-Abbreviated-Patient-Brochure-Spanish

DOWNLOAD ABBREVIATED PATIENT BROCHURE (SPANISH)
english_download

Download-Dxa-FlashcardDownload-Dxa-Flashcard

DOWNLOAD DXA FLASHCARD
english_download

Use the DXA Flashcard during a virtual visit to help your patients better understand the importance of using a DXA to help assess their progress.

Download-Evenity-3d-Bone-ModelDownload-Evenity-3d-Bone-Model

DOWNLOAD EVENITY® 3D BONE MODEL
english_download

Use the EVENITY® 3D Bone Model during a patient’s virtual visit to help you communicate the efficacy and safety of EVENITY®.

Download-Evenity-Transition-Leave-BehindDownload-Evenity-Transition-Leave-Behind

DOWNLOAD EVENITY® TRANSITION LEAVE BEHIND
english_download

Use the EVENITY® Transition Leave Behind to communicate why it is important for your EVENITY® patients to make a plan at the end of their 12 monthly doses.

Amgen PMO Portal

Amgen is dedicated to keeping you up to date with the latest educational resources and providing support as a trusted partner in postmenopausal osteoporosis care

With the PMO Portal, you can learn from leading osteoporosis experts and access on-demand resources anytime, anywhere

Expert Speaker Videos

Expert-Speaker

Clinical Dialogue Tools

Clinical-Dialogue

Educational Brochures

Educational-Brochure
EXPLORE THE PORTAL AND
VIEW RESOURCES
TELEMEDICINE CODING & RESOURCES

CMS GUIDANCE ON CPT AND HCPCS CODES

Medicare Telemedicine Healthcare Provider Fact Sheet

AMA GUIDANCE ON TELEMEDICINE CODING

AMA Quick Guide to Telemedicine in Practice

Important Notice: These links are external third-party websites not affiliated in any way with Amgen. By using these links, you will leave our website. They are being provided as a convenience and for informational purposes only, that they do not constitute an endorsement or an approval by Amgen or any of the products, services, or opinions of the organization or individual. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of any coverage or reimbursement for any product or service. Amgen bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH
EVENITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY® should be discontinued.

Back to Top